Ovarian cancer today and tomorrow: A global assessment by world region and Human Development Index using GLOBOCAN 2020
- PMID: 35322413
- DOI: 10.1002/ijc.34002
Ovarian cancer today and tomorrow: A global assessment by world region and Human Development Index using GLOBOCAN 2020
Abstract
Ovarian cancer remains to have relatively poor prognosis particularly in low-resourced settings. It is therefore important to continually examine the burden of ovarian cancer to identify areas of disparities. Our study aims to provide an overview of the global burden of ovarian cancer using the GLOBOCAN 2020 estimates by country, world region, and Human Development Index (HDI) levels, as well as the predicted future burden by the year 2040 by HDI. Age-standardized incidence and mortality rates for ovarian cancer in 185 countries were calculated by country, world region, and for the four-tier HDI. The number of new cases and deaths were projected for the year 2040 based on demographic projections by HDI category. Approximately 314 000 new ovarian cancer cases and 207 000 deaths occurred in 2020. There were marked geographic variations in incidence rates, with the highest rates observed in European countries with very high HDI and low rates were found in African countries within the lowest HDI group. Comparable mortality rates were observed across the four-tier HDI. Relative to 2020 estimates, our projection for 2040 indicates approximately 96% and 100% increase in new ovarian cancer cases and deaths, respectively, among low HDI countries compared to 19% and 28% in very high HDI countries. Our study highlights the disproportionate current and future burden of ovarian cancer in countries with lower HDI levels, calling for global action to reduce the burden and inequality of ovarian cancer in access to quality cancer care and treatment.
Keywords: cancer disparities; incidence; mortality; ovarian cancer.
© 2022 The World Health Organization. The World Health Organization retains copyright and all other rights in the manuscript of this article as submitted for publication.
Similar articles
-
Global burden of gynaecological cancers in 2022 and projections to 2050.J Glob Health. 2024 Aug 16;14:04155. doi: 10.7189/jogh.14.04155. J Glob Health. 2024. PMID: 39148469 Free PMC article.
-
Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative.Lancet Glob Health. 2023 Feb;11(2):e197-e206. doi: 10.1016/S2214-109X(22)00501-0. Epub 2022 Dec 14. Lancet Glob Health. 2023. PMID: 36528031 Free PMC article.
-
Global burden of thyroid cancer in 2022: Incidence and mortality estimates from GLOBOCAN.Chin Med J (Engl). 2024 Nov 5;137(21):2567-2576. doi: 10.1097/CM9.0000000000003284. Epub 2024 Sep 12. Chin Med J (Engl). 2024. PMID: 39261986 Free PMC article.
-
The Global Landscape of Esophageal Squamous Cell Carcinoma and Esophageal Adenocarcinoma Incidence and Mortality in 2020 and Projections to 2040: New Estimates From GLOBOCAN 2020.Gastroenterology. 2022 Sep;163(3):649-658.e2. doi: 10.1053/j.gastro.2022.05.054. Epub 2022 Jun 4. Gastroenterology. 2022. PMID: 35671803 Review.
-
Global burden of human papillomavirus and related diseases.Vaccine. 2012 Nov 20;30 Suppl 5:F12-23. doi: 10.1016/j.vaccine.2012.07.055. Vaccine. 2012. PMID: 23199955 Review.
Cited by
-
Sensitive and Cost-Effective Tools in the Detection of Ovarian Cancer Biomarkers.Anal Sci Adv. 2024 Oct 24;5(9-10):e202400029. doi: 10.1002/ansa.202400029. eCollection 2024 Oct. Anal Sci Adv. 2024. PMID: 39479573 Free PMC article.
-
Ultrahigh resolution lipid mass spectrometry imaging of high-grade serous ovarian cancer mouse models.Front Chem. 2024 Jan 8;11:1332816. doi: 10.3389/fchem.2023.1332816. eCollection 2023. Front Chem. 2024. PMID: 38260043 Free PMC article.
-
Burden of female breast and five gynecological cancers in China and worldwide.Chin Med J (Engl). 2024 Sep 20;137(18):2190-2201. doi: 10.1097/CM9.0000000000003293. Epub 2024 Aug 29. Chin Med J (Engl). 2024. PMID: 39207303 Free PMC article.
-
Nomograms for predicting overall survival and cancer-specific survival in elderly patients with epithelial ovarian cancer.J Ovarian Res. 2023 Apr 14;16(1):75. doi: 10.1186/s13048-023-01144-y. J Ovarian Res. 2023. PMID: 37059991 Free PMC article. Clinical Trial.
-
Molecular profiling reveals novel therapeutic targets and clonal evolution in ovarian clear cell carcinoma.BMC Cancer. 2024 Nov 14;24(1):1403. doi: 10.1186/s12885-024-13125-5. BMC Cancer. 2024. PMID: 39543535 Free PMC article.
References
REFERENCES
-
- Ferlay J, Ervik M, Lam F, et al. F. B. Global Cancer Observatory: Cancer Today. Vol 2021. Lyon, France: International Agency for Research on Cancer; 2021.
-
- CI5Plus: Cancer Incidence in Five Continents Time Trends. Lyon, France: International Agency for Research on Cancer; 2021.
-
- Cabasag CJ, Arnold M, Butler J, et al. The influence of birth cohort and calendar period on global trends in ovarian cancer incidence. Int J Cancer. 2020;146:749-758.
-
- Coburn SB, Bray F, Sherman ME, Trabert B. International patterns and trends in ovarian cancer incidence, overall and by histologic subtype. Int J Cancer. 2017;140:2451-2460.
-
- Webb PM, Green AC, Jordan SJ. Trends in hormone use and ovarian cancer incidence in US white and Australian women: implications for the future. Cancer Causes Control. 2017;28:365-370.
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical